PTO/SB/08A (08-00)

se type a plus sign (+) inside this box

Unknown

PMP-0003

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete If Known Substitute for form 1449A/PTO 10/584,072 Application Number INFORMATION DISCLOSURE June 22, 2006 STATEMENT BY APPLICANT First Named Inventor Siegfried ANSORGE et al. Unknown Group Art Unit

**Examiner Name** 

(use as many sheets as necessary)

Attorney Docket Number Sheet of

		<del></del>	U.S. P	ATENT DOCUMENTS	
Examiner Initiats *	Cite No.1	U.S. Patent Docum	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document  MM-DD-YYYY
/C.S./	A1	20040127550	A1	Michael TAEGER et al.	07-01-2004
/C.S./	A2	20040138311	A1	Michael TAEGER et al.	07-15-2005
IC.S.I	A3	4871763		DR. MEDAUS GmbH & CO.	10-03-1989
			+		
		•			

Examiner Initials* Ch		Foreign Patent Document			Foreign Patent Document	•	Date of Publication of	Pages, Columns, Lines, Where Relevant	
	Cite No.1	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup>	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T <sup>4</sup>	
	R1	DE	101.25.883	Λ1	SEBUMWERK CMPH	12.12.2002		Δ.	
	82	-DE	101-25-882	A1	ESPARMA Ombi I	12-12-2002		A	
	R3	DF_	35 37 656	Λ1	DR. MEDAUS CmbH	05-22-1086		Ai	
							<u></u>		
				1			[		

Examiner Signature	/Chris Simmons/	Date Considered	09/20/2007	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. 80x 1450, Alexandria, VA 22313-1450.

<sup>1</sup> Unique citation designation number, 2 See attached Kinds of U.S. Patent Documents, 2 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Please type a	plus sign (+)	inside this	<sub>box</sub> →	+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for	form 1449A/P	то		Complete if Known		
				Application Number	10/584,072	
			.OSURE	Filing Date	June 22, 2006	
STATE	MENT	BY APP	LICANT	First Named Inventor	Siegfried ANSORGE et al.	
				Group Art Unit	Unknown	
(us	se as many s	heets as nec	essary)	Examiner Name	Unknown	
Sheet	Sheet 2 of 2		Attorney Docket Number	PMP-0003		

		NON PATENT LITERATURE DOCUMENTS	
Exeminer Initials *	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ,
/C.S./	C1	BIEWENGA, G. et al., "Lipoic acid favors thiosulfinate formation after hypochlorous acid scavenging: a study with lipoic acid derivatives," Arch. Biochem. Biophys., 1994, vol. 312 no. 1, pgs. 114-120.	
/C.S./	C2	TERAMOTO, S. et al., "Effects of angiotension-conversting enzyme inhibitors on spontaneous harvested from patients with or without chronic obstructive pulmonary disease," Jpn. J. Pharmacol., 2000, vol. 83, pgs. 56-62.	
/C.S./	CS	MALERBA, M. et al., "effect of twelve-month therapy with oral ambroxol in preventing exacerbations in patients with COPD: double-blind, randomized, multicenter, placebo-controlled study (The AMEJTHIST Trial)," Pulmonary Pharmacology & Therapeutics, 2004, vol. 17, pgs. 27-34.	
., .,			
		·	
			1

		The second secon	
Examiner Signature	/Chris Simmons/	Date Considered	09/20/2007

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box -> +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

Approved for use through 10/31/2002. OMB 0851-0031

Approved for use through 10/31/2002. OMB 0851-0031

Under the Paperwork Reduction Act of 1995, no persons Substitute for form 1449A/PTO				ere required to respond to a collection of	of information tribles contrains a start Mil control number Complete if Known
				Application Number	USNP of PCT/EP2004/014687
INFO	DRMATION	I DISC	CLOSURE	Filing Date	23 December 2004 (23.12.2004)
STA	TEMENT B	BY AF	PLICANT	First Named Inventor	Siegfried ANSORGE, et al.
				Group Art Unit	unknown
	(use as many s	heets as i	necessary)	Examiner Name	unknown
Sheet	1	of	2	Attorney Docket Number	PMP-0003

		U.S. Patent Document		Date of Dublication of Olivet Decument	
Examiner Initials *	Cite No.1	Number	Kind Code <sup>2</sup> ( <i>if known</i> )	Name of Patentae or Applicant of Cited Document	Date of Publication of Cited Document  MM-DD-YYYY
/C.S./	001	2002/002136	A1	HEBERT, ROLLAND	01-03-2002
.	002	5,972,993	A	PTCHELINTSEV ET AL.	10-26-1999
	003	6,262,019	B1	KELLER, ET AL.	07-17-2001
	004	2004/127550	A1	TAGER, ET AL.	07-01-2004
1/	005	2004/138311	A1	TAEGER, ET AL.	07-15-2004
V	006	2004/219207	A1	ROHNERT, ET AL.	11-04-2004

Examiner Initials*		Foreign Patent Document				Date of Publication of	Pages, Columns, Lines, Where Relovant	
	Cite No.1	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> Number <sup>4</sup> ( <i>if known</i> )	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	Τ*
	007	700	99/55326	A	VIT-IMMUNE, L.O	11-04-1000 -		-003
	008	wo	01/00009		KING'S COLLEGE LONDON; ET AL.	00-20-2001		
	000	wo	02/090414		SERUMWERK BERNBURG AG, ET AL.	12-05-2002		-00-
	010	wo	02/000000	<b>-</b>	ECPARMA CMBH, ET AL.	<del>- 12 05 2002</del>		- 66
	011	<u>CP</u>	1 442 743	<b>A</b>	KEYNEUROTEK AO, ET AL.	00-04-2004		-000

Examiner Signature	/Chris Simmons/	Date Considered	09/20/2007	•

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandría, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

## 'AP20 Rec'd PCT/PTO 22 JUN 2006.

Please type a plus sign (+) inside this box -> +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute	for form 1449A/P	то			compress News 84072
				Application Number	USNP of PCT/EP2004/014687
INFO	RMATION	N DISCI	LOSURE	Filing Date	23 December 2004 (23.12.2004)
STAT	<b>TEMENT B</b>	BY APP	LICANT	First Named Inventor	Siegfried ANSORGE, et al.
_ ,				Group Art Unit	unknown
	(use as many s	heets as ne	cessary)	Examiner Name	unknown
Sheet	2	of	2	Attorney Docket Number	PMP-0003

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т2		
		BUHL R ET AL.: "ANTIOXIDANTS IN THE TREATMENT OF LUNG DISEASES			
	012	MONATSSCHRIFT FUER PHARMAZEUTEN, STUTTGART, DE, Bd. 19, Nr. 10, 1996, PAGES 287-294, XP009044433; ISSN: 0342-9601			
		BERKSON B M: "A CONSERVATIVE TRIPLE ANTIOXIDANT APPROACH TO THE TREATMENT OF HEPATITIS C COMBINATION OF ALPHA LIPOIC ACID (THIOCTIC			
	013	ACID), SILYMARIN, AND SELENIUM: THREE CASE HISTORIES" MEDIZINISCHE KLINIK, Bd. 3, OCTOBER 15, 1999, PAGES 84-89, XP000965112			
		, and the second	-		
<del></del> -					

Examiner Signature /Chris Simmons/	Date Considered	09/20/2007
------------------------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.